CVD Materials Corporation (CVDM), a subsidiary of CVD Equipment Corporation, has teamed up with Dymax Corporation and Keyence Corporation of America to accelerate the development of CVDM’s c-VACNT™ Extracorporeal Membrane Oxygenation (ECMO) platform.
ECMO devices are used to add oxygen and remove carbon dioxide from a blood stream during periods when the patient’s lungs are not performing at appropriate levels.
Typically, ECMO devices are used during heart and lung surgery, but have also recently been used as a last resort for recovery for coronavirus patients.
CVDM will incorporate Dymax’s UV curing materials and Keyence’s 2D scanning technology for manufacturing ECMO prototype test devices based on CVDM’s patent pending c-VACNT™ materials platform.
The multi company collaboration is intended to facilitate manufacturing for a range of novel ECMO devices for in-vitro and in-vivo tests to document their efficiency and safety.
“We believe this multi company collaborative effort will in the next several months result in CVDM providing our c-VACNT™ based prototype ECMO devices to leading ECMO companies for their internal testing and performance evaluation,” said Leonard Rosenbaum, President and CEO of CVD Equipment Corporation.